RIGL Revenue Flow
Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.
- 2026-06-30: Revenue $78.70M; Cost of revenue $8.53M; Research and development $13.96M; Selling, general and administrative $32.64M.
- 2026-03-31: Revenue $58.82M; Cost of revenue $4.61M; Research and development $11.68M; Selling, general and administrative $30.65M.
- 2025-12-31: Revenue $69.80M*; Cost of revenue $5.96M*; Research and development (m); Selling, general and administrative $29.99M*.
- 2025-09-30: Revenue $69.46M; Cost of revenue $4.75M; Research and development (m); Selling, general and administrative $28.94M.
Counterparty Name
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Product or service
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Segment
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.
Historical revenue and expense breakdown
Revenue and expense 3 month
| Period end | Revenue | Cost of revenue | Research and development | Selling, general and administrative | Income tax | Net income |
|---|---|---|---|---|---|---|
| 2026-06-30 | $78.70M | $8.53M | $13.96M | $32.64M | $6.29M | $17.29M |
| 2026-03-31 | $58.82M | $4.61M | $11.68M | $30.65M | $3.00M | $8.65M |
| 2025-12-31 | $69.80M* | $5.96M* | (m) | $29.99M* | -$245.35M* | $268.06M* |
| 2025-09-30 | $69.46M | $4.75M | (m) | $28.94M | -$280.00K | $27.90M |
| 2025-06-30 | $101.69M | $4.50M | $6.82M | $29.26M | $369.00K | $59.61M |
| 2025-03-31 | $53.33M | $4.41M | $8.44M | $27.71M | $65.00K | $11.45M |
| 2024-09-30 | $55.31M | $8.03M | (m) | $27.04M | $0.00 | $12.42M |
| 2024-06-30 | $36.84M | $2.81M | (m) | $28.05M | $0.00 | -$1.03M |
| 2024-03-31 | $29.53M | $2.02M | (m) | $28.45M | $0.00 | -$8.25M |
| 2023-09-30 | $28.13M | $1.27M | (m) | $24.86M | (m) | -$5.69M |
| 2023-06-30 | $26.89M | $1.07M | (m) | $26.31M | (m) | -$6.60M |
| 2023-03-31 | $26.07M | $977.00K | (m) | $27.73M | (m) | -$13.54M |
| 2022-09-30 | $22.41M | $250.00K | (m) | $25.90M | $0.00 | -$19.04M |
| 2022-06-30 | $29.82M | $1.04M | (m) | $26.98M | $0.00 | -$13.49M |
| 2022-03-31 | $16.73M | $121.00K | (m) | $27.40M | $0.00 | -$27.45M |
| 2021-09-30 | $21.54M | $151.00K | (m) | $22.88M | -$136.00K | -$20.95M |
| 2021-06-30 | $26.27M | $129.00K | (m) | $22.38M | -$970.00K | -$13.82M |
| 2021-03-31 | $81.02M | $316.00K | (m) | $22.12M | $1.77M | $39.50M |
| 2020-12-31 | $18.45M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $18.39M | $140.00K | (m) | $17.43M | $0.00 | -$14.17M |
| 2020-06-30 | $16.02M | $279.00K | (m) | $18.92M | $0.00 | (m) |
| 2020-03-31 | $55.76M | $155.00K | (m) | $18.43M | $0.00 | (m) |
| 2019-12-31 | $15.40M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $20.86M | $310.00K | (m) | $18.12M | (m) | (m) |
| 2019-06-30 | $10.41M | $311.00K | (m) | $18.21M | (m) | (m) |
| 2019-03-31 | $12.62M | $107.00K | (m) | $19.95M | (m) | (m) |
| 2018-12-31 | $37.86M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $4.87M | $69.00K | (m) | $18.07M | (m) | (m) |
| 2018-06-30 | $1.79M | $30.00K | (m) | $17.07M | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | $13.49M | (m) | (m) |
| 2017-09-30 | $900.00K | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $3.58M | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | $17.11M | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $16.82M | (m) | (m) | (m) |
Revenue and expense 6 month
| Period end | Revenue | Cost of revenue | Research and development | Selling, general and administrative | Income tax | Net income |
|---|---|---|---|---|---|---|
| 2026-06-30 | $137.52M | $13.13M | $25.64M | $63.29M | $9.30M | $25.94M |
| 2025-06-30 | $155.02M | $8.91M | $15.26M | $56.97M | $434.00K | $71.06M |
| 2024-06-30 | $66.38M | $4.83M | (m) | $56.50M | $0.00 | -$9.28M |
| 2023-06-30 | $52.96M | $2.05M | (m) | $54.03M | (m) | -$20.14M |
| 2022-06-30 | $46.55M | $1.16M | (m) | $54.38M | $0.00 | -$40.94M |
| 2021-06-30 | $107.28M | $445.00K | (m) | $44.50M | $801.00K | $25.68M |
| 2020-06-30 | $71.78M | $434.00K | (m) | $37.35M | $0.00 | (m) |
| 2019-06-30 | $23.03M | $418.00K | (m) | $38.16M | (m) | (m) |
| 2018-06-30 | $1.79M | $30.00K | (m) | $30.56M | (m) | (m) |
| 2017-06-30 | $3.58M | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | $32.22M | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $34.24M | (m) | (m) | (m) |
Revenue and expense 9 month
| Period end | Revenue | Cost of revenue | Selling, general and administrative | Income tax | Net income |
|---|---|---|---|---|---|
| 2025-09-30 | $224.48M | $13.67M | $85.91M | $154.00K | $98.96M |
| 2024-09-30 | $121.68M | $12.86M | $83.54M | $0.00 | $3.14M |
| 2023-09-30 | $81.09M | $3.32M | $78.89M | (m) | -$25.83M |
| 2022-09-30 | $68.96M | $1.41M | $80.28M | $0.00 | -$59.97M |
| 2021-09-30 | $128.83M | $596.00K | $67.38M | $665.00K | $4.73M |
| 2020-09-30 | $90.17M | $574.00K | $54.78M | $0.00 | -$10.51M |
| 2019-09-30 | $43.89M | $728.00K | $56.28M | (m) | (m) |
| 2018-09-30 | $6.65M | $99.00K | $48.63M | (m) | (m) |
| 2017-09-30 | $4.48M | (m) | (m) | (m) | (m) |
Revenue and expense 12 month
| Period end | Revenue | Cost of revenue | Research and development | Selling, general and administrative | Income tax | Net income |
|---|---|---|---|---|---|---|
| 2025-12-31 | $294.28M | $19.62M | $33.30M | $115.90M | -$245.20M | $367.02M |
| 2024-12-31 | $179.28M | $18.65M | $23.38M | $113.06M | $881.00K | $17.48M |
| 2023-12-31 | $116.88M | $7.11M | $24.52M | $105.74M | $0.00 | -$25.09M |
| 2022-12-31 | $120.24M | $1.75M | (m) | $112.45M | (m) | -$58.57M |
| 2021-12-31 | $149.24M | $1.08M | (m) | $91.89M | $605.00K | -$17.91M |
| 2020-12-31 | $108.62M | $895.00K | (m) | $76.60M | (m) | -$29.74M |
| 2019-12-31 | $59.29M | $906.00K | (m) | $74.59M | (m) | -$66.89M |
| 2018-12-31 | $44.51M | $287.00K | (m) | $70.00M | $0.00 | (m) |
| 2017-12-31 | $4.48M | (m) | (m) | $37.83M | $0.00 | (m) |
| 2016-12-31 | $20.38M | (m) | (m) | $20.91M | $0.00 | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | $0.00 | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | $0.00 | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | $0.00 | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |